Rapidly advancing NXT-41x to address significant unmet medical need for plastic and reconstructive surgery, which represents an estimated $1.5 billion U.S. market opportunity Conference call today at 5:00 p.m. ET / 2:00 p.m. PT GAITHERSBURG, Md., Nov. 06, 2025 (GLOBE...
GAITHERSBURG, Md., Oct. 23, 2025 (GLOBE NEWSWIRE) — Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its third quarter 2025 financial results after market close on...
GAITHERSBURG, Md., Oct. 14, 2025 (GLOBE NEWSWIRE) — Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, President and Chief Executive Officer, will present at the LD Micro Main Event XIX...
Industry leader brings 40 years of executive and board experience across the global medical technology sector GAITHERSBURG, Md., Oct. 10, 2025 (GLOBE NEWSWIRE) — Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix...
– Strengthened balance sheet to fully fund development and launch of NXT-41 platform – – Biologics for breast reconstruction represents $1.5 billion U.S. total addressable market – GAITHERSBURG, Md., Oct. 01, 2025 (GLOBE NEWSWIRE) —...
Enter your information and we will be in touch with you.
News Sign Up
Sign up to receive news notifications.
Connect With a Rep
Enter your information and we will be in touch with you.
Learn More Today
Fill out the form below for more information.
Webinar Signup
Sign up to receive webinar notifications.
We use cookies to ensure that we give you the best experience on our website. More information about our site Terms of Use and Privacy Policy provide additional details. Continue on to our site only if you agree with these policies.
